UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative Analysis of Posiphen Pharmacokinetics across Different Species-Similar Absorption and Metabolism in Mouse, Rat, Dog and Human

Biomolecules (Basel, Switzerland), 2024-05, Vol.14 (5), p.582

2024

Volltextzugriff (PDF)

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

Journal of neurology, neurosurgery and psychiatry, 2012-09, Vol.83 (9), p.894-902

2012

Volltextzugriff (PDF)

Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression

Pharmaceutics, 2021-12, Vol.13 (12), p.2109

2021

Volltextzugriff (PDF)

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Alzheimer's research & therapy, 2024-07, Vol.16 (1), p.151-15, Article 151

2024

Volltextzugriff (PDF)

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse

Alzheimer's & dementia : translational research & clinical interventions, 2018, Vol.4 (1), p.37-45

2018

Volltextzugriff (PDF)

Do Mouse Data Lie? For Buntanetap, They Totally Predict Human Outcome

Alzheimer's & dementia, 2023-12, Vol.19 (S12), p.n/a

2023

Volltextzugriff (PDF)

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

Journal of Neural Transmission, 2011-03, Vol.118 (3), p.493-507

2011

Volltextzugriff (PDF)

Posiphen'S Pharmacokinetics and Mechanism-of-action in Mildly Cognitive Impaired Patients

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.e54-e54

Maccecchini, Maria L

2010

Volltextzugriff (PDF)

INHIBITION OF APP/ABETA/CTF BY TRANSLATIONAL INHIBITION OF APP MRNA RESTORES VESICLE TRANSPORT IN TS65DN

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1212-P1212

Maccecchini, Maria L.

2017

Volltextzugriff (PDF)

The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

Journal of Neural Transmission, 2011-03, Vol.118 (3), p.493-507

2011

Volltextzugriff (PDF)

Posiphen lowers amyloid precursor protein and amyloid β as well as acetylcholinesterase levels in culture, animals and humans

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P247-P248

2009

Volltextzugriff (PDF)

Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Motor Function in Parkinson’s Disease

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Cognition in Alzheimer’s Disease

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

Point mutations identify the glutamate binding pocket of the N-methyl- d-aspartate receptor as major site of Conantokin-G inhibition

Neuropharmacology, 2001-11, Vol.41 (6), p.753-761

2001

Volltextzugriff (PDF)

Positive clinical outcomes in two phase 2a studies: ADAS‐COG in Alzheimer’s and MDS‐UPDRS in Parkinson’s patients plus markers of toxic cascade that leads to nerve cell death

Alzheimer's & dementia, 2021-12, Vol.17 (S9), p.n/a

2021

Volltextzugriff (PDF)

Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

Alzheimer's & dementia, 2021-02, Vol.17 (2), p.271-292

2021

Volltextzugriff (PDF)

Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics effects of Posiphen in subjects with early Alzheimer's Disease

Alzheimer's research & therapy, 2024-07, Vol.16 (1)

2024

Volltextzugriff (PDF)

SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia

Brain research, 2003-05, Vol.973 (2), p.252-264

2003

Volltextzugriff (PDF)

P4‐107: Posiphen'S Pharmacokinetics and Mechanism‐of‐action in Mildly Cognitive Impaired Patients

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_21), p.e54-e54

Maccecchini, Maria L.

2010

Volltextzugriff (PDF)

Synthetic Analogues of Conantokin‐G: NMDA Antagonists Acting Through a Novel Polyamine‐Coupled Site

Journal of neurochemistry, 1996-02, Vol.66 (2), p.620-628

1996

Volltextzugriff (PDF)

Synthesis, Resolution, and Biological Evaluation of the Four Stereoisomers of 4-Methylglutamic Acid: Selective Probes of Kainate Receptors

Journal of medicinal chemistry, 1995-07, Vol.38 (14), p.2518-2520

1995

Volltextzugriff (PDF)

P2‐011: Microglia activation in the Alzheimer's brain: Normalization by Posiphen

Alzheimer's & dementia, 2012-07, Vol.8 (4S_Part_7), p.P267-P267

2012

Volltextzugriff (PDF)

Microglia activation in the Alzheimer's brain: Normalization by Posiphen

Alzheimer's & dementia, 2012-07, Vol.8 (4), p.P267-P267

2012

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Animals
(13)
Rats
(9)
Alzheimer's Disease
(8)
Biological And Medical Sciences
(8)
Male
(8)
Neurosciences & Neurology
(7)
Biochemistry & Molecular Biology
(6)
Humans
(6)
Neurology
(6)
Medical Sciences
(5)
Neurosciences
(5)
Posiphen
(5)
Rats, Sprague-Dawley
(5)
Clinical Neurology
(4)
Dose-Response Relationship, Drug
(4)
Female
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Mice
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative Analysis of Posiphen Pharmacokinetics across Different Species-Similar Absorption and Metabolism in Mouse, Rat, Dog and Human

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse

Do Mouse Data Lie? For Buntanetap, They Totally Predict Human Outcome

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

Posiphen'S Pharmacokinetics and Mechanism-of-action in Mildly Cognitive Impaired Patients

INHIBITION OF APP/ABETA/CTF BY TRANSLATIONAL INHIBITION OF APP MRNA RESTORES VESICLE TRANSPORT IN TS65DN

The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

Posiphen lowers amyloid precursor protein and amyloid β as well as acetylcholinesterase levels in culture, animals and humans

Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease

Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Motor Function in Parkinson’s Disease

Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Cognition in Alzheimer’s Disease

Point mutations identify the glutamate binding pocket of the N-methyl- d-aspartate receptor as major site of Conantokin-G inhibition

Positive clinical outcomes in two phase 2a studies: ADAS‐COG in Alzheimer’s and MDS‐UPDRS in Parkinson’s patients plus markers of toxic cascade that leads to nerve cell death

Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics effects of Posiphen in subjects with early Alzheimer's Disease

SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia

P4‐107: Posiphen'S Pharmacokinetics and Mechanism‐of‐action in Mildly Cognitive Impaired Patients

Synthetic Analogues of Conantokin‐G: NMDA Antagonists Acting Through a Novel Polyamine‐Coupled Site

Synthesis, Resolution, and Biological Evaluation of the Four Stereoisomers of 4-Methylglutamic Acid: Selective Probes of Kainate Receptors

P2‐011: Microglia activation in the Alzheimer's brain: Normalization by Posiphen

Microglia activation in the Alzheimer's brain: Normalization by Posiphen

Suchergebnisse filtern